Trial Profile
A Phase 1, Open-label, Dose Escalation Study of Intravenous PRX004 in Subjects With Amyloid Transthyretin (ATTR) Amyloidosis
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs PRX 004 (Primary)
- Indications Amyloidosis; Transthyretin-related hereditary amyloidosis
- Focus Adverse reactions; First in man
- Sponsors Prothena
- 22 Apr 2021 Results presented at the 73rd Annual Meeting of the American Academy of Neurology
- 18 Apr 2021 According to a Prothena media release, positive results from the Phase 1 study of PRX004 presented by Dr. Ole Suhr, as part of the Emerging Science Session at the American Academy of Neurology (AAN) 2021 Virtual Annual Meeting.
- 18 Apr 2021 Results published in the Prothena Media Release